Economic burden of in-hospital AKI: a one-year analysis of the nationwide French hospital discharge database.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
21 Nov 2023
Historique:
received: 05 07 2023
accepted: 10 11 2023
medline: 27 11 2023
pubmed: 22 11 2023
entrez: 22 11 2023
Statut: epublish

Résumé

Although Acute Kidney Injury (AKI) incidence is increasing worldwide, data investigating its cost are lacking. This population-wide study aimed to describe the characteristics and costs of hospital stays with, and without AKI, and to estimate the AKI-associated increases in costs and length of stay (LOS) in three subgroups (major open visceral surgery (MOV), cardiovascular surgery with extracorporeal circulation (CVEC), and sepsis). All hospital stays that occurred in France in 2018 were included. Stay and patient characteristics were collected in the French hospital discharge database and described. Medical conditions were identified using the 10 26,917,832 hospital stays, of which 415,067 (1.5%) with AKI, were included. AKI was associated with 83,553 (19.8%), 7,165 (17.9%), and 15,387 (9.2%) of the stays with sepsis, CVEC, and MOV, respectively. Compared to stays without AKI, stays with AKI were more expensive (median [IQR] €4,719[€2,963-€7782] vs. €735[€383-€1,805]) and longer (median [IQR] 9[4-16] vs. 0[0-2] days). AKI was associated with a mean [95%CI] increase in hospitalization cost of 70% [69;72], 48% [45;50], and 68% [65;70] in the sepsis, CVEC, and MOV groups respectively, after adjustment. This study confirms the major economic burden of in-hospital AKI in a developed country. Interventions to prevent AKI are urgently needed and their cost should be balanced with AKI-related costs.

Sections du résumé

BACKGROUND BACKGROUND
Although Acute Kidney Injury (AKI) incidence is increasing worldwide, data investigating its cost are lacking. This population-wide study aimed to describe the characteristics and costs of hospital stays with, and without AKI, and to estimate the AKI-associated increases in costs and length of stay (LOS) in three subgroups (major open visceral surgery (MOV), cardiovascular surgery with extracorporeal circulation (CVEC), and sepsis).
METHODS METHODS
All hospital stays that occurred in France in 2018 were included. Stay and patient characteristics were collected in the French hospital discharge database and described. Medical conditions were identified using the 10
RESULTS RESULTS
26,917,832 hospital stays, of which 415,067 (1.5%) with AKI, were included. AKI was associated with 83,553 (19.8%), 7,165 (17.9%), and 15,387 (9.2%) of the stays with sepsis, CVEC, and MOV, respectively. Compared to stays without AKI, stays with AKI were more expensive (median [IQR] €4,719[€2,963-€7782] vs. €735[€383-€1,805]) and longer (median [IQR] 9[4-16] vs. 0[0-2] days). AKI was associated with a mean [95%CI] increase in hospitalization cost of 70% [69;72], 48% [45;50], and 68% [65;70] in the sepsis, CVEC, and MOV groups respectively, after adjustment.
CONCLUSION CONCLUSIONS
This study confirms the major economic burden of in-hospital AKI in a developed country. Interventions to prevent AKI are urgently needed and their cost should be balanced with AKI-related costs.

Identifiants

pubmed: 37990296
doi: 10.1186/s12882-023-03396-8
pii: 10.1186/s12882-023-03396-8
pmc: PMC10664266
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

343

Informations de copyright

© 2023. The Author(s).

Références

Crit Care Med. 2018 Feb;46(2):e102-e110
pubmed: 29088005
BMC Nephrol. 2017 Jun 24;18(1):203
pubmed: 28646870
PLoS One. 2016 Jul 26;11(7):e0159944
pubmed: 27459297
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Am Soc Nephrol. 2006 Jun;17(6):1688-94
pubmed: 16641149
Crit Care. 2010;14(2):R46
pubmed: 20346163
Anesth Analg. 2021 Aug 1;133(2):292-302
pubmed: 33684086
BMJ Open. 2022 May 24;12(5):e058205
pubmed: 35613798
Nephrol Dial Transplant. 2014 Jul;29(7):1362-8
pubmed: 24753459
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93
pubmed: 23744003
Nephrol Dial Transplant. 2019 Feb 1;34(2):308-317
pubmed: 30053231
PLoS One. 2019 Feb 7;14(2):e0211541
pubmed: 30730975
Am J Respir Crit Care Med. 2017 Mar 15;195(6):784-791
pubmed: 27635668
Intensive Care Med. 2017 Nov;43(11):1551-1561
pubmed: 28110412
Nephron. 2017;137(4):297-301
pubmed: 28595193
J Hosp Med. 2017 Feb;12(2):70-76
pubmed: 28182800
Intensive Care Med. 2023 Feb;49(2):233-236
pubmed: 36414790
Nat Rev Nephrol. 2018 Oct;14(10):607-625
pubmed: 30135570
J Am Soc Nephrol. 2013 Jan;24(1):37-42
pubmed: 23222124
Intensive Care Med. 2023 Sep;49(9):1079-1089
pubmed: 37432520
Ann Thorac Surg. 2018 Feb;105(2):469-475
pubmed: 29275828
Ann Surg. 2015 Jun;261(6):1207-14
pubmed: 24887982
Intensive Care Med. 2023 Jul 28;:
pubmed: 37505258
Crit Care. 2013 Dec 12;17(6):R292
pubmed: 24330762
Ann Intensive Care. 2020 Oct 20;10(1):145
pubmed: 33079281
Ann Surg. 2018 Jun;267(6):1013-1020
pubmed: 28857811
Clin J Am Soc Nephrol. 2014 Apr;9(4):682-9
pubmed: 24458075

Auteurs

Céline Monard (C)

Service d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France. celine.monard@chu-lyon.fr.
EA 7426, PI3 (Pathophysiology of Injury-Induced Immunosuppression), Université Claude Bernard Lyon 1, Biomérieux, Hospices Civils de Lyon, Lyon, France. celine.monard@chu-lyon.fr.

Thomas Rimmelé (T)

Service d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
EA 7426, PI3 (Pathophysiology of Injury-Induced Immunosuppression), Université Claude Bernard Lyon 1, Biomérieux, Hospices Civils de Lyon, Lyon, France.

Esther Blanc (E)

SA, Global Medical Affairs, bioMerieux, Marcy-L'Étoile, France.

Mélanie Goguillot (M)

stève consultants, Oullins, France.

Stève Bénard (S)

stève consultants, Oullins, France.

Julien Textoris (J)

Service d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
SA, Global Medical Affairs, bioMerieux, Marcy-L'Étoile, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH